Hormonal therapy for metastatic prostate cancer.

Por Small, E J
Publicado em 1994

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Por Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D., Small, E. J.
Publicado em 2009

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Por Small, E J, Higano, C S, Kantoff, P W, Whitmore, J B, Frohlich, M W, Petrylak, D P
Publicado em 2014

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

Por Monk, J.P., Halabi, S., Picus, J., Hussain, A., Philips, G., Kaplan, E., Ahles, T., Gu, Lin, Vogelzang, N., Kelly, W.K., Small, E.J.
Publicado no Cancer (2011)

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Por Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.
Publicado no Ann Oncol (2008)

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Por Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., Tombal, B.
Publicado no Ann Oncol (2015)